Detail

Basic Information Clinical Results Relationship Graph

Basic Information

Gene symbol	S	Synonyms	E2	Type of gene	protein-coding
Chromosome	-	Map location	NC_004718.3 (21492..25259)	dbXrefs
Gene perturbation-related omics dataset	PerturbAtlas
Description	spike glycoprotein

GTO ID	GTC0564
Trial ID	NCT05231005
Disease	COVID-19
Altered gene	S
Therapeutic/Target gene	Therapeutic gene
Therapy	mRNA vaccine
Treatment	BNT162b2\|COMIRNATY\|Tozinameran;mRNA-1273\|Elasomeran\|Spikevax
Location approved	UK, Bahrain, Israel, Canada, US, Rwanda, Serbia, United Arab Emirates, China, Mexico, Kuwait, Singapore, Saudi Arabia, Chile, Switzerland, EU, Ghana, Colombia, Philippines, Indonesia, Australia, Peru, South Korea, New Zealand, Japan, Brazil, Sri Lanka, Vietnam, South Africa, Thailand, Oman, Egypt, Malaysia;UK, Canada, China, Switzerland, Japan, EU, Australia, South Korea, Singapore, US
Phase	Phase4
Recruitment status	Active, Not Recruiting
Title	Fourth BNT162b2 COVID-19 Vaccine Dose - the Sheba HCW Cohort
Year	2021
Country	Israel
Company sponsor	Sheba Medical Center
Other ID(s)	8980-21

Vector information

Vector	lipid nanoparticle

Clinical Result

Cohort1: BNT162b2

Administration route	intramuscular injection
Dosage	BNT162b2, 30 μg
Pts	150
Age	Adult, Older_Adult
Outcome	Geometric mean of antibody titers of each arm, on each time point: after 90 days: IgG geometric mean titer (GMT) of 1442 binding antibody units (BAU)(95% CI, 1194–1741); the GMT of neutralizing antibodies in the mRNA1273 group was 1046 (95% CI, 772–1417); Fourteen days following the fourth dose: anti-RBD immunoglobulin A (IgA), reaching GMT of 4.63 sample-to-cutoff ratio (s/co) (95% CI, 3.88–5.53)
References	PMID: 36513665

Cohort2: Control(BNT162b2)

Administration route	None
Pts	297
Age	Adult, Older_Adult
References	PMID: 36513665

Cohort3: mRNA-1273

Administration route	intramuscular injection
Dosage	mRNA-1273, 50 μg
Pts	129
Age	Adult, Older_Adult
Outcome	Geometric mean of antibody titers of each arm, on each time point: after 90 days: IgG geometric mean titer (GMT) of 854 BAU (95% CI,738–989); the GMT of neutralizing antibodies was 347 (95% CI, 238–507); Fourteen days following the fourth dose: anti-RBD immunoglobulin A (IgA), reaching GMT of 3 s/co (95% CI, 2.57–3.53)
References	PMID: 36513665

Cohort4: Control(mRNA-1273)

Administration route	None
Pts	115
Age	Adult, Older_Adult
References	PMID: 36513665

Relationship Graph

Overview of Knowledge Graph